The global point-of-care molecular diagnostics market size is projected to reach USD 3.4 billion by 2028 from USD 2.0 billion in 2023, at a CAGR of 10.6% during the forecast period. The molecular diagnostics market is experiencing significant growth, primarily driven by several factors. These include the increasing incidence of infectious and chronic diseases, a growing emphasis on decentralized diagnostics, substantial research and development funding, and heightened awareness regarding early detection of infectious diseases. Additionally, the expanding applications of point-of-care diagnostic tests are contributing to market growth. However, there are certain challenges that may hinder the market’s progress. These challenges include the absence of a promising reimbursement scenario, technological advancements being slower in developing economies, and stringent regulatory hurdles related to point-of-care diagnostic test kits.
Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=143524127
The point-of-care molecular diagnostics market is categorized into different segments based on product & service, technology, application, end user, and region. Under the product & service segment, it is further divided into assays & kits, instruments & analyzers, and software & services. In 2022, the assays & kits segment held the largest market share. This significant share can be attributed to the widespread utilization of assays & kits in point-of-care molecular diagnostics, which is considerably higher in comparison to instruments or analyzers.
The point-of-care molecular diagnostics market is divided into various technology segments, including RT-PCR, INAAT, and other technologies. In 2022, the RT-PCR segment emerged as the dominant segment, capturing the largest share in the global market. The substantial market share can be attributed to the increasing utilization of RT-PCR applications in the fields of proteomics and genomics. Furthermore, the availability of portable and user-friendly devices has also contributed to the widespread adoption of RT-PCR technology in point-of-care molecular diagnostics.
Based on end-users, the point-of-care molecular diagnostics market is segmented into physicians’ offices, hospitals & ICUs, research institutes, and other end users. In 2022, The physicians’ offices segment held the largest market share in the point-of-care molecular diagnostics market. This segment’s significant revenue contribution can be attributed to its extensive utilization within physicians’ offices, where it enables rapid delivery of test results within 30 minutes. This quick turnaround time empowers physicians to make prompt treatment decisions without experiencing any delays.
The global market for point-of-care molecular diagnostics is divided into North America, Europe, Asia Pacific, and the Rest of the World. In 2022, North America emerged as the dominant region, capturing the largest market share in the point-of-care molecular diagnostics market. This can be attributed to several factors, including the presence of high healthcare expenditure levels in countries such as the US and Canada. Additionally, the region benefits from significant government support and funding initiatives, further contributing to its leading position among all the regions.
The major players operating in this market are Abbott Laboratories (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux SA (France), Danaher Corporation (US), Quidel Corporation (US), QIAGEN N.V. (Netherlands), Co-Diagnostics, Inc. (US), Biocartis NV (Belgium), Meridian Bioscience, Inc. (US), Thermo Fisher Scientific, Inc. (US), Lucira Health, Inc. (US), Cue Health (US), OpGen, Inc. (US), Binx Health, Inc. (US), Molbio Diagnostics Pct. Ltd. (India), Genomadix (Canada), Visby Medical, Inc. (US), QuikPath PTE Ltd. (Singapore), MD-Bio (US), QuantuMDx Group Ltd. (UK), Aidian Oy (Finland), GeneSTAT Molecular Diagnostics, LLC (US), Labsystems Diagnostics Oy (Finland), Akonni Biosystems (US) and Curetis N.V. (Germany).
Recent Developments of Point of Care Molecular Diagnostics Industry:
In April 2023, QIAGEN N.V. (Netherlands) launched QIAstat-Dx in Japan with a respiratory panel for syndromic testing.
In June 2022, Biocartis NV (Belgium) launched the Rapid CE-marked IVD Idylla GeneFusion Panel for fast treatment decisions in lung cancer.
In May 2022, bioMérieux SA (France) received De Novo FDA Authorization for its BIOFIRE Joint Infection (JI) Panel.
In September 2021, F. Hoffmann-La Roche Ltd. (Switzerland) acquired TIB Molbiol (Germany) to expand its PCR test portfolio with a wide range of assays for infectious diseases.
The global temperature management systems market is projected to reach USD 3.9 Billion by 2028 from USD 3.0 Billion in 2023, at a CAGR of 4.9% during the forecast period. Growth in the temperature management systems market is mainly driven by the increasing prevalence of chronic and infectious diseases which leads various the rising number of surgical procedures. Hypothermia is a common condition observed in surgical procedures due to the usage of anaesthesia; therefore, it leads to increasing number of hypothermia cases expected to grow the market demand of the temperature management systems market during the forecast period.
Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=141546773
Based on the Product, The Temperature Management Systems market, by product, has been segmented into patient warming systems which sub categorized into Surface Warming Systems further categorized into Connective Warming Systems and Conductive warming systems and Intravascular warming systems, patient cooling systems which sub categorized into surface cooling systems and Intravascular cooling Systems and accessories for patient warming/cooling systems. Patient warming systems will drive the growth of the market due to increasing number of hypothermia cases and the growing number of surgical procedures in the countries is another major factor driving the demand for temperature management systems.
Based on the Application, the global Temperature Management Systems market is broadly segmented into Perioperative care, acute care, newborn care, and other applications. Perioperative care is expected to grow highest in the upcoming years due to the increasing number of surgical procedures performed worldwide is the major factor driving the growth of this application segment. Technological advancements, product developments and launches, and growing partnerships between key market players and hospitals are also supporting market growth.
Based on the Medical Speciality Temperature Management Systems is categorized into various segments like general surgery, cardiology, neurology, thoracic surgery, orthopaedic surgery, paediatrics, and other medical specialties (such as ophthalmic, bariatric, and cosmetic surgeries). General surgery is expected to have a highest growth in the upcoming years. The increasing number of general surgery procedures performed in the hospital while lead to the increase demand for the temperature management systems in the ICUs, NICUs and operating rooms.
Based on the region segmentation, the Temperature Management Systems market is divided into North America, Europe, Asia Pacific, and the Rest of the World. North America holds the largest share and expects to dominate the Temperature Management Systems market. Growth in the North American market is mainly driven by the Increasing usage of Increasing growth opportunities in emerging economies and Growing number of contracts and agreements between market players.
3M Company (US), GE Healthcare (US), Dragerwerk AG & Co. KGAA (Germany), Ecolab (US), Asahi-kasei Corporation (Japan), Becton, Dickinson and Company (US), ICU Medical (US), Gentherm Incorporated (US), Inspiration Healthcare Group PLC (UK), Medtronic PLC (Ireland), Stryker Corporation (US), The Surgical Company (Netherlands), Adroit Medical Systems (US), Attune Medical (US), Augustine Surgical, Inc (US), Belmont Medical Technologies (US), Biegler GMBH (Austria), Encompass Group, llc (US), Enthermics, INC (US), Hirtz & Co. KG (Germany), Istanbul Medikal ltd. (Istanbul), Life Recovery Systems (US), Medcare Visions (Germany), TahatAksi (Belarus) and Beijing Eternal Medical Technology Co., Ltd (China)
Recent Developments of Temperature Management Systems Industry
In June 2023, Dragerwerk AG & Co. KGAA has launched the FDA-cleared Babyroo TN300, a new open warmer that offers supportive lung protection and temperature stability from the moment of birth through discharge.
In July 2023, Asahi-kasei Corporation (Japan) signed an agreement with BrainCool, a medical device company specializing in temperature management solutions, for the exclusive distribution of the BrainCool System/IQool System and the IQool System Pads in the US and key markets in Europe. The companies are working toward expanding distribution to select markets in Asia.
In January 2022, ICU Medical completed the acquisition of Smiths Medical from Smiths Group plc. The Smiths Medical business includes syringe and ambulatory infusion devices, vascular access, and vital care products. When combined with ICU Medical’s existing businesses, the combined companies create a leading infusion therapy company with estimated pro forma combined revenues of approximately USD 2.5 billion.
In July 2022, Gentherm acquired Jiangmen Dacheng Medical Equipment Co., Ltd., a manufacturer of medical materials and medical equipment, including patient temperature management solutions.
The PDX model market is projected to reach USD 839 million by 2028 from USD 426 million in 2023, at a CAGR of 14.5% during the forecast period. The key factors driving the growth of the global patient-derived xenograft/ PDX model market are the enhanced preclinical predictability, advancement of personalized medicine, and rise in the prevalence of cancer. However, ethical concerns surrounding the use of animal models along with high associated costs are expected to restrain market growth to a certain extent.
Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=121598251
The patient-derived xenograft/ PDX model market is categorized into five major categories: type, implantation method, tumor type, application, and end user. Based on type, the patient-derived xenograft/ PDX model market is segmented into mouse model and rat model. In 2023, the mouse model segment dominated the patient-derived xenograft/ PDX model market. Growth in this market segment can be attributed to biological similarities of the mice model with human tumors, and the availability of immunodeficient strains is expected to form the largest share segment in the patient-derived xenograft/ PDX model market.
Based on implantation method, the market is categorized into subcutaneous implantation, orthotopic implantation, and other implantation methods. In 2023, the subcutaneous segment accounted for the largest share of the patient-derived xenografts/ PDX models market. The major drivers are propelling the accessibility and ease of Implantation of the subcutaneous method and the cost and time efficiency of the method.
Based on tumor type, the patient-derived xenograft/ PDX model market is categorized into gastrointestinal tumor models, gynecological tumor models, respiratory tumor models, urological tumor models, hematological tumor models, and other tumor models. The hematological tumor models segment accounted for the fastest-growing segment of the tumor type segment of the patient-derived xenograft/ PDX model market. Market growth can largely be attributed to factors such a continuous rise in the incidence of hematological malignancies which is supporting research of treatments against hematological malignancies, and a growing focus on targeted therapies against cancer among others.
Based on application, the patient-derived xenograft/ PDX model market is segmented into preclinical drug development, biomarker analysis, translational research, and biobanking. Among these, the preclinical drug development application segment accounted for the largest share of the patient-derived xenografts/ PDX models application market. The major driver fueling the growth of the patient-derived xenografts/ PDX models market is a constant increase in the number of ongoing clinical trials and the use of PDX models in the development of personalized therapeutic regimens for oncology treatments.
Based on the end user, the segment is categorized into pharmaceutical & biotechnology companies, contract research organizations (CROs), and academic & research institutions. In 2023, the pharmaceutical and biotechnology companies segment dominated the end-user segment with the highest revenue share. Collaborative projects amongst the pharmaceutical and biotechnology companies, rising numbers of drugs in the R&D pipeline, and increasing investment in R&D are propelling the growth of the pharmaceutical and biotechnology companies market.
Based on region, North America accounted for the largest share of the patient-derived xenografts/ PDX models market. The large share of the North American region can be attributed to extensive research focusing on novel oncology therapies, a rise in cancer prevalence, and increased adoption of personalized medicine. Moreover, the APAC region offers lucrative growth potential for the PDX models market. This can be attributed to the supportive regulatory framework, ongoing expansion and modernization of healthcare infrastructure across emerging Asian countries, and public-private initiatives to encourage awareness about personalized medicine.
Major players operating in the patient-derived xenograft/ PDX model market include JSR Corporation (Japan), Wuxi Apptec (China), The Jackson Laboratory (US), Charles River Laboratories International, Inc. (US), Taconic Biosciences, Inc. (US), Oncodesign Precision Medicine (France), Inotiv, Inc. (US), Pharmatest Services (Finland), Hera BioLabs (US), EPO Berlin-Buch GmbH (Germany), Xentech (France), Urosphere (France), Altogen Labs (US), Abnova Corporation (US), Genesis Biotechnology Group (US), Biocytogen Pharmaceuticals Co., Ltd. (China), Creative Animodel (US), BioDuro-Sundia (US), Aragen Life Sciences (India), Shanghai LIDE Biotech Co., Ltd. (China), Certis Oncology Solutions (US), InnoSer (Netherlands), IVRS AB (Sweden), Beijing IDMO Co. Ltd. (China), and Shanghai Chempartner Co. Ltd. (China).
The global airway management devices market is projected to reach USD 2.4 Billion by 2028 from USD 1.8 Billion in 2022, at a CAGR of 5.6% during the forecast period. The growth of this market is majorly driven by increasing demand for emergency and intensive care units, increasing growth in healthcare infrastructure development and rising pre-term birth population is supporting the growth of the market. However, dearth of skilled professional for airway management procedures may restrain the market growth during the forecast period.
Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=116806061
Based on type, the airway management devices market has been segmented into infraglottic devices, supraglottic devices, laryngoscopes, resuscitators, cricothyrotomy kits, and other airway management devices. The Infraglottic airway management devices segment accounted for the largest market share in 2022. Increasing number of surgical procedures and emergency care is driving the adoption of infraglottic devices in the market.
Based on patient age, the airway management devices market has been categorized into adult patients and pediatric /neonatal patients. In 2022, adult patients segment dominates the segment due to increasing prevalence of chronic diseases in geriatric population.
Based on applications, the airway management devices market is segmented into anesthesia, emergency medicine and others. The anesthesia application segment is expected to observe highest growth rate during the forecast period which can be attributed to the growing need for maintaining a safe breathing passage to decrease the risk of anesthesia-related complications during surgery.
Based on end users, the airway management devices market is segmented into hospitals, ambulatory care settings, home-care settings, and others. Hospital & diagnostic centers observe the highest growth rate during the forecast period attributed to the growing number of emergency care and intensive care beds across hospitals worldwide.
Based on the region segmentation, the airway management devices market is divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America holds the largest share and expects to dominate the airway management devices market. Growth in the North American market is mainly driven by increasing number of favorable reimbursement policies investments and rising number of acute and ambulatory care settings.
Major Players:
Medtronic (Ireland), ICU Medical, Inc. (US), Teleflex Incorporated (US), Ambu A/S (Denmark), ConvaTec Group Plc (UK), KARL STORZ SE & CO. KG (Germany), Flexicare Group Ltd. (UK), Intersurgical Ltd. (UK), SunMed LLC (US), Vyaire (US), Verathon Inc. (US), Sourcemark LLC (US), VBM Medizintecnik GmBH (Germany), Mercury Enterprises (US), Atos Medical (Sweden), P3 Medical (UK), Henan Tuoren Medical Device Co. Ltd. (China), BOMImed (Canada), Mederen Neotech Ltd. (Israel), and Medis Medical (UK) Ltd.(China), Olympus Corporation (Japan), Armstrong Medical Ltd. (Eakin Healthcare Group) (UK), Nihon Kohden Corporation (Japan) and Shenzen Hugemed Medical Technical Development Co. Ltd. (China)
Recent Developments
In 2022, SunMed Holdings (US) announced a strategic partnership with Securisyn Medical LLC (US) to enhance ventilated patient safety and broader smooth tube and catheter security.
In 2022, Coloplast A/S acquired Atos Medical to add a new chronic business segment – ENT & Respiratory Care, which will run as a separate strategic unit, operating on shared Coloplast infrastructure.
In 2022, ICU Medical, Inc. acquired Smiths Medical (US), which includes a syringe and ambulatory infusion devices, vascular access, and vital care products. When combined with ICU Medical’s existing businesses, it created a leading infusion therapy company.
The Healthcare analytical testing services Market is projected to reach a valuation of USD 7.4 billion in 2024, with an anticipated surge to USD 12.6 billion by 2029, exhibiting a CAGR of 11.2% throughout the forecast period. There are noticeable investments in research and development (R&D) in pharma and biopharma industry to expand manufacturing capacities in response to the escalating demand for drugs. The healthcare analytical testing services market is growing due to increasing demand for solutions, challenges in developing proper techniques, and government initiatives to bolster testing capabilities. However, lack of skilled professionals and rising cost and competition will affect market growth negatively during the forecast period.
Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=108923833
The healthcare analytical testing services market is segmented based on the end users it serves, which include pharmaceutical and biopharmaceutical companies, medical device manufacturers, forensic labs, hospitals and clinics, and cosmetic and nutraceutical producers. Among these segments, pharmaceutical companies stood out as the largest contributors to the market in 2023. This prominence can be attributed to the increasing reliance of these companies on outsourcing healthcare analytical testing services. By outsourcing such services, pharmaceutical and biopharmaceutical companies can optimize their profit margins and focus more effectively on their core competencies, such as drug discovery and development. This strategic shift allows them to leverage the specialized expertise and resources of analytical testing service providers, thereby driving growth in the market.
Based on type, the healthcare analytical testing services market encompasses various segments such as bioanalytical testing, physical characterization, method development and validation, stability testing, batch-release testing, raw material testing, microbial testing, genomic services, and environmental monitoring services. In 2023, the biohealthcare analytical testing services segment emerged as the dominant contributor to the market. This segment’s significant share can be attributed to its offering of comprehensive bioanalytical testing solutions catering to a diverse array of drug types available in the market, spanning vaccines, small molecules, biologics, and more. The breadth of services provided within this segment addresses the multifaceted needs of pharmaceutical, biopharmaceutical, and medical device companies, thus driving its prominence in the market landscape.
North America has taken the forefront in the healthcare analytical testing services market, boasting the largest share among the segmented regions. This prominence is fueled by several factors contributing to the region’s robust growth. Firstly, In the US, a pivotal player in the region, there has been a considerable surge in the pharmaceutical and biopharmaceutical companies, thereby driving the demand for healthcare analytical testing services. Furthermore, the presence of well-established market players within the US market further strengthens North America’s position, as these entities contribute to the market’s overall growth and innovation. Additionally, the region benefits from advanced healthcare infrastructure and regulatory frameworks conducive to the expansion of healthcare analytical testing services, reinforcing its leading status in the market.
Major Players:
Eurofins Scientific (Luxembourg), Laboratory Corporation of America Holdings (US), SGS S.A. (Switzerland), Charles River Laboratories (US), WuXi AppTec Co. Ltd. (China), Element Materials Technology (UK), Thermo Fisher Scientific, Inc. (US), Pace Analytical Services LLC (US), Intertek Group plc (UK), IQVIA Inc. (US), Merck KGaA (Germany), Source BioScience (UK), Almac Group (UK), ICON Plc (Ireland), Frontage Laboratories, Inc. (US), STERIS Plc (US), Sartorius AG (Germany), ALS Life Science (US), Syneos Health, INC (US), Medpace Holdings, Inc. (US), LGC Limited (UK), Parexel International Corporation (US), Celerion (US). Pharmaron (China), and BioAgilytix Labs (US).
The global sleep apnea oral appliances market is projected to reach USD 0.9 Billion by 2028 from USD 0.4 Billion in 2023, at a CAGR of 15.2% during the forecast period. The growth of this market is majorly driven by the increasing number of customized or personalised oral appliance, and collaboration between dentists and sleep specialists. However, the risks associated with sleep apnea oral appliances for obstructive sleep apnea treatment may restrain the market growth.
Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=105423877
Sleep Apnea Oral Appliances Market by Product (Mandibular Advancement Devices (MAD), Tongue-Retaining Devices (TRD)), Purchase Type (Physician-prescribed), Gender (Male, Female), Age Group, Distribution Channel (Online, Retail) – Global Forecast to 2028
Based on product, the sleep apnea oral appliances market is divided into three main categories—mandibular advancement devices (MADs), tongue-retaining devices (TRDs), and Daytime Nighttime Appliance (DNA). In 2022, the mandibular advancement devices segment accounted for the largest share of the sleep apnea oral appliances market. The large share of this segment can be attributed to technological advancements have improved the design, comfort, and effectiveness of MADs.
Base on purchase type, the sleep apnea oral appliances market is segmented into – physician-prescribed/ customized oral appliances and online OTC oral appliances. The physician-prescribed/customized oral appliances segment accounted for the largest share of the sleep apnea oral appliances market in 2022. Factors supporting the growth of this segment include rising demand for effective alternatives for managing sleep apnea under the guidance and recommendation of healthcare professionals.
On the basis of gender, the sleep apnea oral appliances market is segmented into male and female. In 2022, the male segment dominated this market. The large share of this segment can be attributed to the anatomical differences in upper airway, throat and neck structure between men and women
On the basis of region, the global sleep apnea oral appliances market is categorized into the North America, Europe, Asia-Pacific, and the RoW segments. North America holds the largest market share in 2022 due to the ongoing research and development initiatives by companies in North America for sleep apnea oral appliances innovation and rising aging population. Other factors boosting the demand for this market include advancement in telemedicine and remote monitoring to make sleep apnea treatment more accessible for patients.
Major Companies:
SomnoMed (Australia), ResMed (US), Whole You, Inc. (US), ProSomnus Sleep Technologies (US), Vivos Therapeutics, Inc. (US), Open Airway Dental Solutions Ltd. (Canada), Panthera Dental (Canada), Airway Management (US), Apnea Sciences (US), DynaFlex (US), OravanOSA (US), Myerson LLC (US), MPowrx Health & Wellness (Canada), The Snore Reliever Company, LLC (US), The Pure Sleep Company (US), Tomed GmbH (Germany), The Aurum Group (Canada), Erkodent Erich Kopp GmbH (Germany), OSCIMED SA (Switzerland), SICAT GmbH & Co. Kg. (Germany), Glidewell (US), ApnoMed (US), ZYPPAH (US), Dream Systems Dental Sleep Laboratory (US), and Alive Med (UAE)
Recent Developments of Sleep Apnea Oral Appliances Industry
In 2023, Vivos Therapeutics, Inc. (US) DNA appliance was granted 510(k) clearance from the U.S. Food & Drug Administration (or FDA) as a Class II medical device in December 2022 for the treatment of snoring and mild to moderate OSA in adults.
In 2022, ResMed (US) acquired the German-based clinical, financial, and operational solutions provider MEDIFOX DAN (Germany) to drive leadership in out-of-hospital software solutions.
In 2021, SomoMed (Australia) conducted SomSUMMIT ’21, which aimed to enhance research, education, and awareness of oral appliance therapy as a primary solution to successful OSA treatment.
The global PCR technologies Market is expected to reach USD 18.3 billion by 2027 from an estimated USD 12.5 billion in 2022, at a CAGR of 8.0% from 2022 to 2027.
Polymerase chain reaction (PCR) is a well-established technique used for the in vitro amplification of a given nucleotide (such as DNA). This technique is used to prepare multiple copies of a gene and to synthesize a large number of DNA molecules from a given DNA sample. This is done by separating the two strands of the DNA, marking its location with a primer, and using a DNA polymerase enzyme to synthesize and assemble a copy of the gene alongside a template.
Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=96291811
PCR Technologies Market by Technique (Conventional, qPCR, dPCR), Product (Instrument, Reagents, Software), Application (Genotyping, Sequencing, Gene Expression, Diagnostics), End User (Academia, Pharma-Biotech, Applied) – Global Forecast to 2027
Growth in this market is largely driven by factors such as the rising incidence of target infectious diseases and genetic disorders, continuous advancements in PCR technologies and increasing investments.
The demand for early disease diagnosis and treatment has driven the R&D in developing genetic technologies and product development. This rise in R&D activity is supported by an increase in investments and the availability of funds and grants. For instance, in March 2018, vc (WGGC) and the Universities of Cologne, Bonn, and Düsseldorf (Germany), received ~USD 5.98 million (EUR 5.3 million) for a joint competence center from the German Research Foundation (DFG).
Government and federal agencies across the globe are recognizing the role of qPCR and dPCR products (such as instruments, reagents, and software) in genomics-based research. In the last decade, the qPCR and dPCR market has witnessed several funding initiatives by government and private agencies to support genomic research. In October 2020, Visby Medical (US), an infectious disease diagnostic company, received Phase 2 funding from the National Institutes of Health (NIH) as part of its Rapid Acceleration of Diagnostics (RADx) initiative. In addition, Centre d’innovation Génome Québec et Université McGill (Canada) received ~USD 10 million in funding from federal and provincial investments on February 2019. The funding will be utilized for projects in the field of bioinformatics, epigenomics, and precision medicine, among other fields (Source: McGill University, Canada). These initiatives are aimed at conducting medical genomics-based studies in personalized medicine, including PCR-based disease diagnosis and treatment.
Thus, with the growing availability of financial support for sustaining R&D in disease-targeted genomics research activities, the demand for PCR products is expected to increase in the coming years.
On the other hand, issues related to high instrument costs of dPCR and the limitations of PCR technologies are expected to restrict the market growth to a certain extent in the coming years.
dPCR instruments integrates scientific technologies such as PCR, microfluidics, and nanofabrication, to conduct a typical PCR analysis. These instruments are small, however, their development requires big investments and extensive scientific validation on a nanoscale level. As of 2022, the average price of a dPCR instrument in the US is reported to be USD 55,000–120,000. Such high prices have resulted in the subdued adoption of dPCR instruments among price-sensitive end users. Moreover, the dPCR instruments are expensive compared to qPCR instruments (~USD 90,000).
Due to the preference for cheaper genomic techniques (such as gel electrophoresis and traditional PCR), the demand for premium-priced dPCR instruments and reagents is restricted, especially among researchers and small CROs and pharmaceutical & biotechnology companies.
On the basis of product, the global PCR technologies market is broadly classified into instruments, reagents and consumables, and software and services. In 2021, the reagents and consumables segment accounted for the largest share of the PCR technologies market. This is mainly due to the expanding applications of dPCR, increasing number of dPCR-based analytical procedures among institutional researchers (such as CROs and pharma-biotech companies), and the rising availability of novel dPCR reagents worldwide. Additionally, the expansion of the application base of the dPCR technology in genetic/molecular research, clinical diagnosis, and forensics is expected to result in the commercialization of novel dPCR reagents.
The global Bio Decontamination market is projected to reach USD 339 million by 2028 from USD 238 million in 2023, at a CAGR of 7.3% during the forecast period. The growth of this market is majorly driven by Increased outsourcing of bio decontamination services and Rising growth in pharmaceutical & biotechnology industries. However, the Rising adoption of single-use medical devices may restrain the growth of this market.
Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=104696777
Based on Product & Service, the Bio Decontamination Market is segmented into Consumables, Equipment, & Services. The Services segment is projected to grow at the highest CAGR during the forecast period. The major factors contributing to the growth of this market are: The services segment is growing mainly due to its low cost (as compared to the costs incurred while setting up in-house decontamination facilities, buying equipment, allotting storage space, and in repair & maintenance).
Based on the Agent type, the Bio Decontamination Market is segmented into Hydrogen Peroxide, Chlorine Dioxide, Peracetic Acid, Nitrogen Dioxide, The Hydrogen Peroxide segment is expected to dominate the market during the forecast period due Vaporized hydrogen peroxide is one of the commonly used bio decontamination agents moreover it has wide application areas, including pharmaceutical & medical device manufacturing, biosciences & biotechnology research labs, hospitals & healthcare facilities, and veterinary applications. Several regulations also support the use of hydrogen peroxide, such as the US EPA.
Based on the Type, the Bio Decontamination Market is segmented into Chamber Decontamination, Room Decontamination. The Chamber Decontamination segment is expected to dominate the market during the forecast period because the power consumption of bio decontamination chambers is less than room decontamination. It is also less costly, which has stimulated the adoption of chamber bio decontamination.
Based on the end user, the Bio Decontamination Market is segmented into Pharmaceutical & Medical Device Manufacturing Companies, Life Sciences & Biotechnology Research Organizations, Hospitals & Healthcare Facilities. The Pharmaceutical & Medical Device Manufacturing Companies is expected to dominate the market during the forecast period due to Bio decontamination is an integral part of the pharmaceutical manufacturing process. Pharmaceutical manufacturing companies are facing increased pressure to ensure the integrity of their products and maintain manufacturing facilities that are free from contamination of any kind. Failure to maintain good manufacturing practices (GMP) has resulted in severe consequences. Similarly, medical device manufacturing companies also must follow strict guidelines to prevent and control medical devices from being contaminated at their facilities.
Based on the region, the Bio Decontamination Market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). In 2022, North America accounted for the largest share of the Bio Decontamination Market. Growth in the North American market is mainly driven by the growing demand for bio decontamination technologies from the healthcare industry to minimize the occurrence of hospital-acquired infections (HAIs) and the increasing presence of major manufacturers in the region.
The significant players in the Bio Decontamination market are Steris PLC (US), Ecolab (US), TOMI Environmental Solutions, Inc (US), JCE Biotechnology (France), Fedegari Autoclavi SpA (Italy), Zhejiang TAILIN Bioengineering Co., LTD (China), Howorth Air Technology Ltd. (UK), Solidfog Technologies (Belgium), ClorDiSys (US), Amira (Italy)
Recent Developments
In July 22, Ecolab’s (US) Bioquell HPV-AQ received an authorized approval for use in all territories of the European Union and the European Economic Area.
In Dec 2022, the TOMI Environmental Solutions, Inc (US) launched new SteraMist products, which include the Select Plus-a hybrid product consisting of the Company’s current Surface Select and Environment systems. (The system is 24 volts, allowing for universal outlet usage and convert more of the hydrogen peroxide BIT Solution to hydroxyl radicals thus lowering H2O2 PPM levels allowing for faster turnaround time).
MarketsandMarkets expect the Global Veterinary API Market is projected to reach USD 11.9 billion by 2028 from USD 8.5 billion in 2023, at a CAGR of 6.9% the forecast period. Factors like Increasing emphasis on disease prevention and control, growing animal population and pet ownership, rising demand for veterinary medicines, and growing awareness of animal welfare are expected to drive the development and growth of the veterinary API market.
Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=91801752
Veterinary API Market by API Type (Antimicrobials (Fluoroquinolones, Tetracyclines), Vaccines, Hormones, Antimicrobials, Anti-inflammatory, Hormones), Synthesis Type, Route of Administration, and Animal Type – Global Forecast to 2028
In this report, the Veterinary API market is segmented on the basis of API Type, Synthesis Type, Route of Administration, Animal Type, and region.
Based on API Type, market segments are divided into six types such as Parasiticides, Vaccines, Antimicrobials, Anti-inflammatory, Hormones, and Other Veterinary APIs. The Parasiticides segment accounted for the largest share of the global Veterinary API market in 2022. The rising R&D investment on veterinary API manufacturing, rising parasitic infection in companion and livestock animals are additional factors that are expected to boost market expansion throughout the projected period.
Based on Synthesis type, Veterinary API market is segmented into three types such as Chemical based API, Biological API, and Highly potent API. The Chemical based API segment accounted for the largest share of the global Veterinary API market in 2022. Wide Range of Therapeutic Options for chemical based API manufacturing, Good stability and longer shelf life compared to some biological APIs are some of the factors that are expected to boost the segment in this market.
Based on Route of Administration, Veterinary API market is segmented into four types such as Oral, Injectable, Topical, and Others. The Oral segment accounted for the largest share of the global Veterinary API market in 2022. Wide applicability in various animal species, easy to administer all the medications, and flexibility in dosing are some of the factors to grow the segment in this market.
Based on Animal Type, Veterinary API market is segmented into four types such as companion and livestock animals. The companion animals segment accounted for the largest share of the global Veterinary API market in 2022. Increasing product portfolio by pharmaceutical companies for companion animals healthcare and advances in veterinary medicines are the factors to grow the segment in this market.
The Veterinary API Market is categorized into five geographical regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In terms of market share, North America was the dominant region for Veterinary APIs globally in 2022. It is anticipated that a major drivers impacting the North America market growth would be development of advanced drug delivery systems, novel formulations, and innovative diagnostic tools, well-established regulatory standards for veterinary pharmaceuticals, and advanced veterinary healthcare infrastructure.
The prominent players in the global Veterinary API Market are Phibro Animal Health Corporation (US), Fabbrica Italiana Sintetici S.p.A. (Italy), Sequent Scientific Ltd. (India), Excel Industries Ltd. (India), NGL Fine-Chem Ltd. (India), Insulnsud Pharma (Spain), Menadiona Sl (Spain), Rochem International Inc. (US), and Shaanxi Hanjiang Pharmaceutical Group Co. Ltd. (China)
Recent Developments of Veterinary API Industry
- In 2021, Sequent Scientific Ltd. (India) received WHO–GENEVA approval for API Praziquantel (Anthelmintic) under the prequalification program.
- In 2020, Sequent Scientific Ltd. Opened a state-of-the-art animal health R&D center in Mumbai, India.
The global Medical Display Market is projected to reach USD 2.9 billion by 2028 from USD 2.3 billion in 2023, at a CAGR of 5.2% during the forecast period. There are several factors which drive the medical display market like rising technological advancements, increasing demand for diagnostic imaging, rising awareness and adoption of minimally invasive procedures and surge in telemedicine and remote diagnostics.
In this report, the Medical Display Market is segmented on the basis of technology, panel size, resolution, display color, application and region.
Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=74058413
Medical Display Market by Technology (LED-Backlit LCD Displays, CCFL-Backlit LCD Displays, OLED Displays), Panel Size (Under 22.9 inch panels, 23.9-26.9 inch panels, 27-41.9 inch panels), Resolution, Display Color, Application – Global Forecast to 2028
Based on technology, the market is segmented into LED-Backlit LCD Displays, CCFL-Backlit LCD Displays, OLED Displays. The U LED-Backlit LCD Displays segment accounted for the largest share of the global medical display market in 2022. Increasing Demand for LED medical displays due to its availability in a wide range of sizes and offer numerous advantages over conventional CCFL-backlit LCD display, such as clear medical images, bright color, good stability, high brightness, high efficiency, long service life, and low energy consumption. LED backlighting technology provides higher brightness and contrast ratios compared to CCFL backlights.
Based on Panel Size, the Medical Display Market is segmented into Under 22.9 Inch Panels, 23.0-26.9 Inch Panels, 27.0-41.9 Inch Panels, Above 42 Inch Panels. 27.0-41.9 Inch Panels accounted for the largest share of the Medical display Market in 2022. This panels strike a balance between screen real estate and space requirements. They are versatile enough to be used in various medical imaging applications, including radiology, surgical suites, or dental clinics are some of the factors that contribute to the big proportion of this market.
Based on Resolution, the Medical Display Market is segmented into Up to 2MP, 2.1–4MP, 4.1–8MP, Above 8MP. 4.1–8MP accounted for the largest share of the Medical display Market in 2022. These displays can support 10-bit input for each RGB color, provide sRGB over 99, and display more than one billion colors simultaneously to ensure accurate color reproduction in operating rooms. Considering the above-mentioned functionalities, coupled with the growing volume of surgical procedures, the demand for these displays is expected to increase in the coming years.
Based on Display Color, the Medical Display Market is segmented into Color and Monochrome & Grayscale. Color segment accounted for the largest share of the Medical display Market in 2022. Factors such as enhanced visualization, technological advancements, increasing complexity of medical imaging, improved patient care and safety, integration with picture archiving and communication systems (PACS), and advantages of color displays over grayscale displays such as enhanced contrast and differentiation, improved depth perception, enhanced communication and collaboration, multi-modality application are responsible for the large adoption of color displays in the healthcare industry
Based on Application, the Medical Display Market is segmented into Diagnostic, Surgical/ Interventional, Dentistry and others. Diagnostic segment accounted for the largest share of the Medical display Market in 2022. Factors such as the large share of this segment can be attributed to the rapidly increasing prevalence of diseases such as cancer and the increasing number of patients being screened using imaging systems are some of the factors that contribute to the big proportion of this market.
The Medical Display Market is divided into five regions based on geography: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2021, North America held the highest market share for the global Medical Display Market. North America has a major share of the market because of the presence of good healthcare infrastructure, as well as the rising R&D investment on medical devices.
Barco NV (Belgium), Eizo (Japan), Sony Electronics Inc. (Japan), Lg Electronics (South Korea), Novanta (US), FSN Medical Technologies (South Korea), Advantech (Taiwan), Quest International (US), Steris (UK), Jusha Medical (China), Siemens Healthineers Ag (Germany), Double Black Imaging (US), HP Development Co. Ltd (US), Stryker (US), and Coje Display (South Korea)